• Calpain Inhibitor I, ALLN: Application in Apoptosis and Inju

  2026-05-27

  Calpain Inhibitor I, ALLN is designed for selective inhibition of calpain and cathepsin proteases in apoptosis assays and ischemia-reperfusion injury models. It should not be used where water-solubility is critical or in diagnostic/medical workflows. The following guide distills product-specific and best-practice protocol guidance for effective laboratory use.

• Pseudo-UTP: Enhancing mRNA Synthesis with Pseudo-Modified Ur

  2026-05-26

  Pseudo-UTP empowers researchers to synthesize high-stability, low-immunogenicity mRNA, accelerating vaccine and gene therapy innovation. This guide details experimental best practices, troubleshooting insights, and workflow upgrades that unlock the full potential of pseudo-modified uridine triphosphate for next-gen RNA applications.

• Pregnenolone Carbonitrile: Microbiota, PXR, and Liver Protec

  2026-05-26

  Explore how Pregnenolone Carbonitrile modulates the gut-liver axis to protect against sepsis-induced liver injury. This article unpacks the compound's dual action as a PXR agonist and antifibrotic agent, revealing practical insights for hepatic detoxification studies.

• Mubritinib–HSA Recognition: Implications for Cancer Drug Des

  2026-05-25

  This study elucidates the molecular interaction between mubritinib, an electron transport chain inhibitor, and human serum albumin (HSA), using multi-spectroscopic and computational approaches. The findings clarify how drug–protein binding influences pharmacokinetics, with direct implications for the optimization of anti-proliferative agents in cancer research.

• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-05-25

  This study leverages structure-based virtual screening to identify potent natural product inhibitors of NSP15, a key endoribonuclease in SARS-CoV-2. The findings highlight thymopentin and oleuropein as promising leads for antiviral development, with implications for targeted COVID-19 therapies.

• Griseofulvin in Aneugenicity Profiling: Advanced Mechanistic

  2026-05-24

  Explore how Griseofulvin, a microtubule associated inhibitor, enables precise dissection of aneugenic mechanisms in antifungal drug research. This article uniquely connects reference assay innovations with actionable protocols for advanced cell cycle studies.

• Thrombin B Chain: Precision in Fibrin Matrix and Platelet St

  2026-05-23

  Discover how the Thrombin B Chain Fragment from APExBIO elevates reproducibility and mechanistic fidelity in fibrinogen to fibrin conversion and platelet activation assays. This article bridges advanced protocol optimization and troubleshooting with translational insights from angiogenesis research, empowering next-generation experimental design.

• MRSA: Molecular Mechanisms, Epidemiology, and Research Tools

  2026-05-22

  Turner et al. provide a comprehensive review of methicillin-resistant Staphylococcus aureus (MRSA), highlighting its genetic basis, clinical impact, and the ongoing challenges in treatment and epidemiological control. Their synthesis underscores the need for precise laboratory models to study resistance and inform new therapeutic strategies.

• Laminin (925-933): Practical Guide for Cell Adhesion & Migra

  2026-05-22

  Laminin (925-933) offers a defined, receptor-specific peptide tool to dissect cell adhesion, migration, and chemotaxis in basement membrane protein research. This product is optimal for cell-based assays requiring precise modulation of laminin receptor pathways but should not be used for diagnostic or therapeutic purposes.

• Pharmacokinetics of CSBTA in MASH: Impact of Disease on Expo

  2026-05-21

  This study details how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids in mice. By linking pathological status to changes in drug metabolism and transporter expression, the findings guide rational dosage regimens for MASLD/MASH therapies.

• Epalrestat: Aldose Reductase Inhibitor for Translational Res

  2026-05-21

  Epalrestat delivers unmatched precision as an aldose reductase inhibitor, empowering advanced workflows in diabetic complication, neuroprotection, and cancer metabolism studies. Its validated solubility and purity set a new standard for reproducibility and translational impact.

• Amphotericin B in Translational Fungal Research: Beyond the

  2026-05-20

  This thought-leadership article explores how the mechanistic properties of Amphotericin B—an iconic polyene antifungal antibiotic—are catalyzing strategic advances in translational fungal infection research. Integrating new insights into biofilm drug resistance, TLR2/CD14 immune signaling, and practical workflow optimization, it offers actionable guidance for researchers seeking to overcome clinical and experimental challenges, with due focus on APExBIO's Amphotericin B (SKU: B1885).

• KAS-ATAC Sequencing: Mapping Accessible and ssDNA Regions Ge

  2026-05-20

  The reference study introduces KAS-ATAC sequencing, a protocol leveraging N3-kethoxal labeling to simultaneously map physically accessible and single-stranded DNA regions in native chromatin. This innovation refines our ability to interrogate cis-regulatory element activity and transcriptional dynamics at high resolution, offering researchers a powerful approach for dissecting genome regulation in situ.

• Carvedilol Phosphate in Ischemia–Reperfusion Injury Models

  2026-05-19

  Carvedilol Phosphate enables precise modeling of beta-adrenergic signaling and macrophage polarization in hepatic and cardiac ischemia–reperfusion injury. This article details experimental workflows, troubleshooting strategies, and protocol enhancements that set APExBIO's high-purity non-selective beta blocker apart for cardiovascular pharmacology research.

• Cimetidine in Translational Research: Beyond Acid Inhibition

  2026-05-19

  This article re-examines Cimetidine through a mechanistic and translational lens, revealing its unique partial agonist profile at the H2 receptor, antitumor potential in gastrointestinal cancers, and strategic advantages for blood-brain barrier (BBB) research. Integrating recent breakthroughs in high-throughput BBB modeling, we offer actionable guidance for researchers aiming to bridge preclinical discovery and clinical application. The discussion synthesizes evidence from peer-reviewed studies and advanced workflows, positioning APExBIO’s Cimetidine as a pivotal tool for cancer and CNS research.

450 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page